The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022Development of a Radiolabeled Tracer for Detecting Insoluble Protein Aggregates in Parkinson’s Disease
Study Rationale: Many neurodegenerative disorders are caused by a toxic buildup of insoluble protein aggregates. In Parkinson’s disease (PD), accumulation of alpha-synuclein contributes to the death...
-
Expanding Biological Understanding of Parkinson's Disease, 2022Deep Phenotyping of Parkinson's Disease Relevant Mitochondrial and Autophagic Mechanisms in Human iPSC-derived Neural Cells
Study Rationale: The causes of Parkinson’s disease (PD) are not fully understood. However, impairment in the function of mitochondria, the powerhouses of the cell, and in autophagy, a process whereby...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2022Esya PD360: A Multi-parametric Platform for Establishing a Novel Lysosome-based Biomarker and Identifying Therapeutic Interventions for Parkinson’s Disease
Study Rationale: Lysosomes are sub-cellular compartments responsible for clearing proteins that are prone to aggregation, a process called autophagy. Dysfunctional lysosomes with increased acidity and...
-
Research Grant, 2022Perspective and Consensus on Prevention Planning for Parkinson’s Disease
Study Rationale: In October 2022, a conference on “Planning for Prevention of Parkinson's: A trial design forum” gathered a broad range of stakeholders interested in preventing Parkinson’s disease (PD...
-
Research Grant, 2022Registry for the Advancement of DBS in Parkinson’s Disease (RAD-PD)
Study Rationale: RAD-PD is a quality improvement patient registry project that will address clinical questions about deep brain stimulation (DBS) therapy that cannot be practically answered via the...
-
Therapeutic Pipeline Program, 2022Evaluating the Efficacy of a mGluR5 Modulator in Preclinical Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is one of many neurodegenerative diseases that are characterized by the buildup of misfolded protein aggregates in the brain. Preclinical data suggest that...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.